Volume 6, Issue 2 (Avicenna Journal of Pharmaceutical Research, Dec 2026)
Avicenna J Pharma Res 2026, 6(2): 123-132 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shariat Razavi F. Physiological and Pharmaceutical Determinants of Brain Drug Bioavailability: Barriers, Transport Mechanisms, and Advanced Nanotechnological Strategies. , Avicenna J Pharma Res. 2026; 6 (2) :123-132
URL: http://ajpr.umsha.ac.ir/article-1-125-en.html
URL: http://ajpr.umsha.ac.ir/article-1-125-en.html
1 Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran & 2 Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
Abstract: (5 Views)
Efficient delivery of therapeutic agents to the central nervous system (CNS) remains challenging due to the restrictive blood–brain barrier (BBB). This review evaluates physiological and pharmaceutical determinants of brain bioavailability and discusses emerging nanotechnology-based strategies. Brain bioavailability is influenced by BBB integrity, efflux transporter activity, cerebral blood flow, pathological conditions, molecular properties, and nanocarrier design. Integrating physiological understanding with rational pharmaceutical design is essential for improving future CNS therapeutics.
Keywords: Blood–brain barrier, Brain bioavailability, CNS drug delivery, Efflux transporters, Nanoparticles, Receptor-mediated transport, Intranasal delivery
Type of Study: Applicable |
Subject:
Special
Received: 2026/11/14 | Accepted: 2027/03/1 | Published: 2026/11/14
Received: 2026/11/14 | Accepted: 2027/03/1 | Published: 2026/11/14
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
